SG&A expenses increased 18.9%, primarily from personnel and travel costs due to the measured expansion of our teams globally, as well as one-time consulting costs associated with our planned facilities expansion.

Oct 29, 2024 / CFO / receipt, needs a key / Angie Weirich, CFO | earnings call 2024-10-29 | transcript 4cd4dbc7-46f6-4cde-82f9-3583b2f65f22 | chars 12037-12249 | segment 11

The change results mainly from personnel costs, driven by increasing headcount and variable compensation programs, travel spend returning to normal, and expanding training activities as we launch our hybrid AF therapy and continue awareness across our platforms with a combination of mobile cadaver labs and training courses.

Aug 4, 2021 / CFO / receipt, needs a key / Angie Weirich, CFO | earnings call 2021-08-04 | transcript 191ca54f-d13f-441e-892c-125261bdf224 | chars 13668-13993 | segment 13

This decrease was primarily driven by lower variable compensation expense as well as decreases in travel, training, and meeting costs due to continued limitations on in-person group events and trade shows that were canceled, delayed, or transitioned to virtual platforms.

Nov 5, 2020 / CFO / receipt, needs a key / Angie Weirich, CFO | earnings call 2020-11-05 | transcript 02045e14-d72b-4de1-819b-363af83ae287 | chars 16828-17099 | segment 17

The majority of this improvement is driven by lower variable compensation, travel and training and other commercial costs, which we expect to be restored to historical levels as our top line improves.

Nov 5, 2020 / CFO / receipt, needs a key / Angie Weirich, CFO | earnings call 2020-11-05 | transcript 02045e14-d72b-4de1-819b-363af83ae287 | chars 17858-18058 | segment 18